Optibrium Acquires BioPharmics LLC
August 31, 2023
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
- Buyers
- Optibrium
- Targets
- BioPharmics LLC
- Industry
- Software
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pharmaron Acquires 82.54% of Biortus Biosciences
October 28, 2025
Healthcare Services
Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.
-
Bruker Corporation Acquires biocrates life sciences ag
June 3, 2025
Biotechnology
Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.
-
QuartzBio (Precision for Medicine) Acquires SolveBio
January 24, 2023
Cloud & SaaS
QuartzBio, a business unit of Precision for Medicine, has acquired SolveBio and integrated its enterprise biomarker and genomic data management platform into QuartzBio’s end-to-end SaaS suite. The acquisition expands QuartzBio’s capabilities for sample inventory, biomarker data management and enterprise-level visibility to better serve pharmaceutical and biotech clients in clinical research and development.
-
VeriSIM Life Acquires Molomics Biotech
May 11, 2022
Biotechnology
VeriSIM Life, an AI-driven virtual drug development company based in San Francisco, has acquired Molomics Biotech SL, a Barcelona-based AI-enabled drug discovery firm. The acquisition integrates Molomics' AI + Human Collective Intelligence discovery technology into VeriSIM's BIOiSIM platform to accelerate and improve success rates in drug discovery, including work on Parkinson's disease.
-
Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities
February 14, 2022
Biotechnology
Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.
-
Ott Scientific Acquires American Bionostica
April 1, 2021
Medical Devices
Ott Scientific has acquired American Bionostica, Inc., a developer and manufacturer of specialty lateral flow assays; the acquisition was effective April 1 and ABI will operate inside Ott Scientific’s Ethos Biosciences subsidiary. The American Bionostica team will join Ott Scientific, with expanded research and production capacity planned at Ott Scientific’s new ISO13485/cGMP space in Logan Township, New Jersey.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.